Equities Research Analysts’ Updated EPS Estimates for April 8th (AA, AB, ABBV, ACAD, AIG, ARTV, BHST, BMY, BPMC, BWIN)

Equities Research Analysts’ updated eps estimates for Tuesday, April 8th:

Alcoa (NYSE:AA) had its underperform rating reissued by analysts at Bank of America Co.. The firm currently has a $26.00 target price on the stock, down from their previous target price of $58.00.

AllianceBernstein (NYSE:AB) had its equal weight rating reiterated by analysts at Barclays PLC. The firm currently has a $34.00 price target on the stock.

AbbVie (NYSE:ABBV) had its neutral rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. The firm currently has a $194.00 target price on the stock.

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $28.00 target price on the stock.

American International Group (NYSE:AIG) had its neutral rating reiterated by analysts at JPMorgan Chase & Co.. JPMorgan Chase & Co. currently has a $91.00 price target on the stock, up from their previous price target of $83.00.

Artiva Biotherapeutics (NASDAQ:ARTV) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $23.00 price target on the stock.

BioHarvest Sciences (NASDAQ:BHST) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $14.00 target price on the stock.

Bristol-Myers Squibb (NYSE:BMY) had its neutral rating reissued by analysts at The Goldman Sachs Group, Inc.. The Goldman Sachs Group, Inc. currently has a $55.00 target price on the stock, down from their previous target price of $67.00.

Blueprint Medicines (NASDAQ:BPMC) had its buy rating reaffirmed by analysts at Needham & Company LLC. The firm currently has a $133.00 price target on the stock.

The Baldwin Insurance Group (NASDAQ:BWIN) had its neutral rating reaffirmed by analysts at JPMorgan Chase & Co.. The firm currently has a $45.00 price target on the stock, up from their previous price target of $39.00.

Chegg (NYSE:CHGG) had its underweight rating reissued by analysts at JPMorgan Chase & Co..

Clene (NASDAQ:CLNN) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $31.00 price target on the stock.

Clene (NASDAQ:CLNN) had its buy rating reiterated by analysts at D. Boral Capital. The firm currently has a $23.00 price target on the stock.

Clearside Biomedical (NASDAQ:CLSD) had its buy rating reaffirmed by analysts at Needham & Company LLC. The firm currently has a $4.00 target price on the stock.

CorMedix (NASDAQ:CRMD) had its buy rating reissued by analysts at D. Boral Capital. D. Boral Capital currently has a $15.00 target price on the stock.

Cytokinetics (NASDAQ:CYTK) had its buy rating reaffirmed by analysts at Needham & Company LLC. The firm currently has a $72.00 price target on the stock.

Dominion Energy (NYSE:D) had its underweight rating reaffirmed by analysts at JPMorgan Chase & Co.. The firm currently has a $52.00 price target on the stock, down from their previous price target of $59.00.

DocGo (NASDAQ:DCGO) had its buy rating reaffirmed by analysts at Needham & Company LLC. The firm currently has a $4.00 target price on the stock.

Esperion Therapeutics (NASDAQ:ESPR) had its buy rating reaffirmed by analysts at Needham & Company LLC. The firm currently has a $5.00 price target on the stock.

Fluence Energy (NASDAQ:FLNC) had its equal weight rating reaffirmed by analysts at Barclays PLC. The firm currently has a $5.00 price target on the stock, down from their previous price target of $9.00.

Harmony Biosciences (NASDAQ:HRMY) had its buy rating reiterated by analysts at Needham & Company LLC. They currently have a $50.00 price target on the stock.

ICU Medical (NASDAQ:ICUI) had its hold rating reissued by analysts at Needham & Company LLC.

Inozyme Pharma (NASDAQ:INZY) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $15.00 target price on the stock.

Ionis Pharmaceuticals (NASDAQ:IONS) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $60.00 price target on the stock.

Ideal Power (NASDAQ:IPWR) had its hold rating reaffirmed by analysts at Westpark Capital.

KalVista Pharmaceuticals (NASDAQ:KALV) had its buy rating reaffirmed by analysts at Needham & Company LLC. The firm currently has a $28.00 price target on the stock.

Kura Oncology (NASDAQ:KURA) had its outperform rating reiterated by analysts at Wedbush. They currently have a $36.00 target price on the stock.

Liberty Energy (NYSE:LBRT) had its equal weight rating reissued by analysts at Wells Fargo & Company. Wells Fargo & Company currently has a $11.00 target price on the stock, down from their previous target price of $20.00.

Legend Biotech (NASDAQ:LEGN) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $75.00 price target on the stock.

Lexeo Therapeutics (NASDAQ:LXEO) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $23.00 price target on the stock.

Microvast (NASDAQ:MVST) had its buy rating reissued by analysts at HC Wainwright. They currently have a $3.00 target price on the stock.

NewAmsterdam Pharma (NASDAQ:NAMS) had its buy rating reissued by analysts at Needham & Company LLC. Needham & Company LLC currently has a $42.00 target price on the stock.

Nyxoah (NASDAQ:NYXH) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $15.00 target price on the stock.

Ocular Therapeutix (NASDAQ:OCUL) had its buy rating reiterated by analysts at Needham & Company LLC. They currently have a $15.00 target price on the stock.

OncoCyte (NASDAQ:OCX) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $4.25 target price on the stock.

Pacira BioSciences (NASDAQ:PCRX) had its buy rating reaffirmed by analysts at Needham & Company LLC. They currently have a $32.00 price target on the stock.

Vaxcyte (NASDAQ:PCVX) had its buy rating reaffirmed by analysts at Needham & Company LLC. Needham & Company LLC currently has a $90.00 price target on the stock.

Pfizer (NYSE:PFE) had its neutral rating reissued by analysts at The Goldman Sachs Group, Inc.. They currently have a $25.00 target price on the stock, down from their previous target price of $32.00.

Phio Pharmaceuticals (NASDAQ:PHIO) had its buy rating reissued by analysts at HC Wainwright. They currently have a $4.00 price target on the stock.

Praxis Precision Medicines (NASDAQ:PRAX) had its buy rating reiterated by analysts at Needham & Company LLC. They currently have a $85.00 price target on the stock.

Prelude Therapeutics (NASDAQ:PRLD) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $5.00 target price on the stock.

Revolution Medicines (NASDAQ:RVMD) had its buy rating reaffirmed by analysts at Needham & Company LLC. Needham & Company LLC currently has a $59.00 target price on the stock.

Recursion Pharmaceuticals (NASDAQ:RXRX) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $11.00 price target on the stock.

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $80.00 target price on the stock, up from their previous target price of $70.00.

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $66.00 target price on the stock.

Signet Jewelers (NYSE:SIG) had its equal weight rating reiterated by analysts at Wells Fargo & Company. Wells Fargo & Company currently has a $70.00 target price on the stock, down from their previous target price of $80.00.

SuRo Capital (NASDAQ:SSSS) had its outperform rating reaffirmed by analysts at Barrington Research. The firm currently has a $8.00 price target on the stock.

TScan Therapeutics (NASDAQ:TCRX) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $9.00 target price on the stock.

Trevi Therapeutics (NASDAQ:TRVI) had its buy rating reaffirmed by analysts at Needham & Company LLC. Needham & Company LLC currently has a $24.00 price target on the stock.

Verrica Pharmaceuticals (NASDAQ:VRCA) had its neutral rating reiterated by analysts at HC Wainwright.